TITLE

INTELLIPHARMACEUTICS FILES ANDA FOR GENERIC SEROQUEL XR

PUB. DATE
May 2011
SOURCE
Worldwide Biotech;May2011, Vol. 23 Issue 5, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the Abbreviated New Drug Application of Intellipharmaceutics International Inc. for psychotropic agent Seroquel XR used for schizophrenia and bipolar disorder. Intelliphramaceutics chief executive officer Dr. Isa Odidi said that the U.S. Food and Drug Administration (FDA) filing does not only show the capabilities of their Hypermatrix technology but also the flexibility of their company to match a number of drug delivery profiles. Hypermatrix is a drug delivery platform that can be used for a wide range of drugs.
ACCESSION #
60242738

 

Related Articles

  • Intellipharmaceutics Completes pre-IND for Rexista.  // Biotech Business;Jun2012, Vol. 25 Issue 6, p6 

    The article reports that Intellipharmaceutics International Inc. has already completed a pre-Investigational New Drug (pre-IND) meeting for its Rexistaâ„¢ oxycodone. It states that Intellipharmaceutics met with the U.S. Food and Drug Administration (FDA) for the discussion of the development...

  • Drug shortages still at crisis levels. Talsma, Julia // Drug Topics;Jun2013, Vol. 157 Issue 6, p32 

    The article focuses on the U.S. Food and Drug Administration (FDA) report depicting the shortage of drug delivery in the U.S. It mentions that the shortage lead to the national problems for physicians, pharmacists, and patients. It mentions that the common drug classes that fall short are...

  • Anaesthesia gasket leak poses risk to patients & bystanders.  // Reactions Weekly;12/8/2012, Issue 1431, p3 

    The article reports that health professionals have been notified by the U.S. Food and Drug Administration of a recall of Mindray A3 and A5 anesthesia delivery systems, as the gasket on some affected devices may not be able to be seated correctly within the canister, causing the device to leak.

  • Reusable pen helps diabetics reach treatment goals.  // Drug Topics;8/23/2004, Vol. 148 Issue 16, p8 

    Reports that the U.S. Food and Drug Administration approved the OptiClik reusable pen for the administration of insulin glargine for injection.

  • FDA to adopt new pediatric suicidality warning for antidepressant labelling.  // Formulary;Oct2004, Vol. 39 Issue 10, p478 

    This article reports that the analysis of independently reviewed pediatric suicidality data for antidepressants by the U.S. Food and Drug Adminsitration (FDA) was discussed on September 13 and 14 at a joint meeting of the Psychopharmacologic Drugs and Pediatric Advisory committees. The...

  • Meds are no defense against suicide. Perina, Kaja // Psychology Today;Sep/Oct2002, Vol. 35 Issue 5, p20 

    Focuses on a study conducted by physician Arif Kafan among patients in clinical trials of psychotropic medications. Failure of psychotropic medications to reduce suicide; Review of U.S. Food and Drug Administration reports on psychotropic drugs; Calculation of the risk of suicide among patients.

  • Psychiatry.  // PharmaWatch: CNS;Jan2011, Vol. 10 Issue 1, p9 

    The article offers updates on psychiatry diseases by pharmaceutical companies in the U.S. The result of the third phase III worldwide clinical trial of Latuda for schizophrenia treatment was announced by Sunovion Pharmaceuticals Inc. The Food & Drug Administration has approved Sun Pharmaceutical...

  • Diabetic Doubts. Auerbach, Michael // Pharmaceutical Processing;Jul2010, Vol. 25 Issue 7, p6 

    The author focuses on the issues hounding the development of diabetic medications in the U.S. He notes that the Food and Drug Administration (FDA) is preparing to review a diabetes drug for possible links to heart disease, which is also said to be very promising for the millions of diabetics who...

  • NEEDLE FREE. Jesitus, John // Cosmetic Surgery Times;Jul2007, Vol. 10 Issue 6, p26 

    The article focuses on Transderm Ionto System in the U.S. It states that the system is the only transdermal delivery device that has been approved by the Food and Drug Administration (FDA) as an alternative to injections, and the only device that can deliver heavy molecules such as botulinum...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics